Sign in
CompletedPhase 1/2

ADX-629 Therapy for Sjogren-Larsson Syndrome

Key facts

Who runs it
University of Nebraska
Where
Omaha, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
8 people enrolled
Started
2 Jan 2023
Ended
1 Apr 2026
Type of study
Interventional
Treatments tested
  • ADX-629
Record updated
5 May 2026

Who can take part

Age
5 years to 50 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Patricipant or participant's guardian is willing to provide written informed consent prior to the initiation of any study procedures. Assent will be solicited from participant intellectually capable of providing assent
  • Participant is willing to comply with all study procedures and availability for the duration of the study
  • Participant is 5-50 years of age at the time of enrollment
  • Participant has a genetically-confirmed diagnosis of SLS with two pathogenic sequence variants in ALDH3A2
  • Participant has active ichthyosis and neurologic symptoms of spasticity
  • Participant is able to swallow oral tablet medication and is willing to adhere to the study regimen
  • Participant is willing to suspend use of all topical creams 7 days before initial baseline evaluation and before the 12-week center visit
  • Participant has not been treated with any experimental drug for 1 month before baseline visit and during ADX-629 treatment
  • Participant who is sexually active agrees to use adequate contraception throughout the duration of the study, as follows:
  • For females of child-bearing potential: Negative pregnancy test at Baseline and compliant with a medically approved contraceptive regimen during the study or documented to be surgically sterile or postmenopausal
  • For sexually-active men: Compliant with a barrier contraceptive regimen during the study

Who cannot take part

  • History of any malignancy within 5 years of screening except for basal cell or squamous cell in situ skin carcinomas or carcinoma in situ of the cervix that has been treated with no evidence of recurrence
  • Participant is currently receiving immunosuppressive therapy, including intermittent or low-dose corticosteroids and is not able or willing to suspend its use for a period from 2 weeks before and throughout the study
  • Participant is currently receiving and refuses to interrupt any systemic or topical medication that is excluded
  • Participant received an investigational systemic or topically administered prescription drug within 30 days before enrollment
  • Participant has received botulinum toxin (Botox) injections within 6 months of enrollment
  • Participant is known to be human immunodeficiency virus (HIV) positive or has other known immunodeficiency
  • Participant has evidence of an active systemic or skin infection, including severe acute respiratory syndrome (SARS-CoV-2)
  • History or presence of gastrointestinal, hepatic disease, moderate or severe hepatic impairment (defined as Child-Pugh Class B and Class C) or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drug
  • History of any other condition that, in the opinion of the Investigator, would compromise the participant's ability to comply with the protocol or that might compromise the participant's safety or the interpretation of the study results
  • Participant has a known allergic reaction to any ingredients of study drug formulation
  • History of significant tachycardia, bradycardia, acute or chronic cardiovascular disease, or any clinically significant abnormalities in rhythm or conduction detected on electrocardiogram (ECG), or QT interval corrected for heart rate using Fridericia's formula (QTcF) of >440 ms or <340 ms during screening
  • Acute or chronic renal disease, moderate or severe renal impairment, history of renal disease, or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 calculated by Chronic Kidney Disease Epidemiology (CKD-EPI) equation
  • Participant is currently participating in any other therapeutic clinical study
  • Participant is pregnant, intending to become pregnant, or breastfeeding

Where in United States

  • University of Nebraska Medical CenterOmaha, United States

About the trial

What the trial wants to find out

This research study will determine whether orally administered ADX-629 is safe and has biochemical efficacy in participants with Sjögren-Larsson syndrome (SLS), a rare inherited disorder of fatty aldehyde metabolism The disease is caused by bi-allelic mutations in ALDH3A2, which results in deficient activity of fatty aldehyde dehydrogenase (FALDH) and leads to the build-up of harmful long-chain (C16-C20) aldehydes and alcohols. Accumulation of these lipids and their metabolic products in skin, brain and eyes is responsible for the symptoms, which persist lifelong. ADX-629 is an aldehyde trapping agent that is expected to eliminate fatty aldehydes and negate aldehyde toxicity, improve the biochemical abnormalities and have clinical efficacy for SLS.

Read full original descriptionShow less

The primary objective of this clinical protocol is to determine whether ADX-629 is safe and tolerable for use in SLS subjects. The secondary objective is to determine the efficacy of ADX-629 in reversing the biochemical abnormalities in SLS. Exploratory objectives are to evaluate the short-term clinical effects of ADX-629 on neurologic, cutaneous and ophthalmologic disease in SLS. Participants will be treated with ADX-629 for 12 weeks and monitored for safety and biochemical efficacy.

The group in the trial

  • ADX-629 treatmentTreatment being tested

    Open label treatment with ADX-629

    Treatment: ADX-629

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label, Phase 1/2, Single-Site Study of the Safety, Biochemical Efficacy, and Exploratory Clinical Effects of Oral ADX-629 in Subjects With Sjögren-Larsson Syndrome
Record updated
5 May 2026